Efficacy and safety of donepezil in patients with dementia with Lewy bodies: Preliminary findings from an open-label study

被引：48
作者：
Mori, S
Mori, E
Iseki, E
Kosaka, K
机构：
[1] Matsushita Mem Hosp, Dept Neurol, Osaka 5708540, Japan
[2] Tohoku Univ, Grad Sch Med, Dept Behav Neurol & Cognit Neurosci, Sendai, Miyagi 980, Japan
[3] Juntendo Univ, Sch Med, Tokyo Koto Geriatr Med Ctr, Dept Psychiat, Tokyo 113, Japan
[4] Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan
来源：
PSYCHIATRY AND CLINICAL NEUROSCIENCES | 2006年 / 60卷 / 02期
关键词：
cholinesterase inhibitors; dementia with Lewy bodies; donepezil; efficacy; treatment;
D O I：
10.1111/j.1440-1819.2006.01485.x
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The objectives of the present study were first to determine the feasibility of conducting a randomized clinical trial of 5 mg/day donepezil in patients with mild to moderate dementia with Lewy bodies (DLB) and second, to obtain preliminary data of possible intervention effects. Twelve patients with probable DLB were evaluated at weeks 4, 8, and 12 using modified Neuropsychiatric Inventory (NPI) with an extra domain to additionally evaluate fluctuation in cognitive functions (NPI-11); the Japanese version of Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-J cog); and the Unified Parkinson's Disease Rating Scale (UPDRS). The NPI-11 scores were significantly improved at weeks 8 and 12 compared with baseline. Despite a significant improvement in ADAS-J-cog at week 4, no more improvement was noted thereafter. Deterioration was not noted in UPDRS scores. Donepezil is expected to be therapeutically useful and safe in treating DLB patients, indicating marked improvements in behavioral and psychological symptoms of dementia (BPSD) rather than in cognitive deficit, without deteriorating parkinsonism.
引用
收藏
页码：190 / 195
页数：6
相关论文
共 25 条
[1]   Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study [J].
Aarsland, D ;
Laake, K ;
Larsen, JP ;
Janvin, C .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 72 (06) :708-712
[2]   Fluctuations in attention - PD dementia vs DLB with parkinsonism [J].
Ballard, CG ;
Aarsland, D ;
McKeith, I ;
O'Brien, J ;
Gray, A ;
Cormack, F ;
Burn, D ;
Cassidy, T ;
Starfeldt, R ;
Larsen, JP ;
Brown, R ;
Tovee, M .
NEUROLOGY, 2002, 59 (11) :1714-1720
[3]   DIAGNOSIS AND EVALUATION OF DEMENTIA [J].
COREYBLOOM, J ;
THAL, LJ ;
GALASKO, D ;
FOLSTEIN, M ;
DRACHMAN, D ;
RASKIND, M ;
LANSKA, DJ .
NEUROLOGY, 1995, 45 (02) :211-218
[4]   THE NEUROPSYCHIATRIC INVENTORY - COMPREHENSIVE ASSESSMENT OF PSYCHOPATHOLOGY IN DEMENTIA [J].
CUMMINGS, JL ;
MEGA, M ;
GRAY, K ;
ROSENBERGTHOMPSON, S ;
CARUSI, DA ;
GORNBEIN, J .
NEUROLOGY, 1994, 44 (12) :2308-2314
[5]   Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 12-week interim analysis [J].
Edwards, KR ;
Hershey, L ;
Wray, L ;
Bednarczyk, EM ;
Lichter, D ;
Farlow, M ;
Johnson, S .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 17 :40-48
[6]  
Fahn S., RECENT DEV PARKINSON, V2, P153, DOI DOI 10.1002/ANA.410220556
[7]  
Finkel S I, 1996, Int Psychogeriatr, V8 Suppl 3, P497
[8]  
FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198
[9]  
Hirono N, 1997, No To Shinkei, V49, P266
[10]   PARKINSONISM - ONSET PROGRESSION AND MORTALITY [J].
HOEHN, MM ;
YAHR, MD .
NEUROLOGY, 1967, 17 (05) :427-&
123